Shepherd et al. summarized the prognostic and predictive roles of KRAS mutation status and subtype in early-stage resected NSCLC in four adjuvant chemotherapy trials and found that KRAS mutation status was not a significant independent prognostic factor, especially for amino acid substitution mutations in the 12th codon [20]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.